Zachary Stanton, Bonnie Woloschuk, Alexander Tamm, Ryan Hung, Adwait Trivedi, Michael Kolinsky, Nawaid Usmani, Lindsay Rowe, Ronald Moore, Frank Wuest, Jonathan Abele
{"title":"<sup>18</sup>F-PSMA-1007 PET/CT Demonstrates Higher Accuracy for Biochemically Recurrent Prostate Cancer Compared to Contemporary Conventional Imaging.","authors":"Zachary Stanton, Bonnie Woloschuk, Alexander Tamm, Ryan Hung, Adwait Trivedi, Michael Kolinsky, Nawaid Usmani, Lindsay Rowe, Ronald Moore, Frank Wuest, Jonathan Abele","doi":"10.1155/aiu/8550174","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The goal of this study was to compare the accuracy of <sup>18</sup>F-PSMA-1007 PET/CT to contemporary conventional imaging (contrast-enhanced CT scan of the chest, abdomen, and pelvis and a <sup>99m</sup>Tc-MDP whole body bone scan with SPECT/CT of the torso) in the setting of biochemically recurrent prostate cancer.</p><p><strong>Methods: </strong>This prospective nonrandomized Phase II cohort study clinical trial included 85 patients with biochemically recurrent prostate cancer (previous therapy). <sup>18</sup>F-PSMA-1007 whole body PET/CT imaging was performed in all patients, with conventional imaging (contrast-enhanced CT scan of the chest, abdomen, and pelvis and a <sup>99m</sup>Tc-MDP whole body bone scan with SPECT/CT of the torso) then performed within 12 days. PROMISE criteria were used for PET/CT interpretation. After a minimum 1-year follow-up period, lesion-level and patient-level analyses were performed based on previously published reference criteria (Lawhn-Heath et al. 2019). The accuracy data were compared. Referring physicians were surveyed to help determine if the scans altered treatment. Categorical variables were compared using the McNemar test (<i>p</i> < 0.05 significant).</p><p><strong>Results: </strong>53 patients with a total of 72 evaluable lesions were included in the analysis. <sup>18</sup>F-PSMA-1007 PET/CT had a higher sensitivity than conventional imaging on a lesion level (100% compared with 58.3%) and higher overall accuracy on a patient level (90.6% compared with 62.3%, <i>p</i> < 0.05). The referring physicians felt that the <sup>18</sup>F-PSMA-1007 PET/CT scans were beneficial to the clinical care of the patient in 90.6% of cases.</p><p><strong>Conclusion: </strong>Overall, the findings support the use of <sup>18</sup>F-PSMA-1007 over conventional imaging in the evaluation of patients with biochemically recurrent prostate cancer. <b>Trial Registration:</b> ClinicalTrials.gov.identifier: NCT04733768.</p>","PeriodicalId":7490,"journal":{"name":"Advances in Urology","volume":"2026 ","pages":"8550174"},"PeriodicalIF":0.6000,"publicationDate":"2026-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13333931/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/aiu/8550174","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: The goal of this study was to compare the accuracy of 18F-PSMA-1007 PET/CT to contemporary conventional imaging (contrast-enhanced CT scan of the chest, abdomen, and pelvis and a 99mTc-MDP whole body bone scan with SPECT/CT of the torso) in the setting of biochemically recurrent prostate cancer.
Methods: This prospective nonrandomized Phase II cohort study clinical trial included 85 patients with biochemically recurrent prostate cancer (previous therapy). 18F-PSMA-1007 whole body PET/CT imaging was performed in all patients, with conventional imaging (contrast-enhanced CT scan of the chest, abdomen, and pelvis and a 99mTc-MDP whole body bone scan with SPECT/CT of the torso) then performed within 12 days. PROMISE criteria were used for PET/CT interpretation. After a minimum 1-year follow-up period, lesion-level and patient-level analyses were performed based on previously published reference criteria (Lawhn-Heath et al. 2019). The accuracy data were compared. Referring physicians were surveyed to help determine if the scans altered treatment. Categorical variables were compared using the McNemar test (p < 0.05 significant).
Results: 53 patients with a total of 72 evaluable lesions were included in the analysis. 18F-PSMA-1007 PET/CT had a higher sensitivity than conventional imaging on a lesion level (100% compared with 58.3%) and higher overall accuracy on a patient level (90.6% compared with 62.3%, p < 0.05). The referring physicians felt that the 18F-PSMA-1007 PET/CT scans were beneficial to the clinical care of the patient in 90.6% of cases.
Conclusion: Overall, the findings support the use of 18F-PSMA-1007 over conventional imaging in the evaluation of patients with biochemically recurrent prostate cancer. Trial Registration: ClinicalTrials.gov.identifier: NCT04733768.
期刊介绍：
Advances in Urology is a peer-reviewed, open access journal that publishes state-of-the-art reviews and original research papers of wide interest in all fields of urology. The journal strives to provide publication of important manuscripts to the widest possible audience worldwide, without the constraints of expensive, hard-to-access, traditional bound journals. Advances in Urology is designed to improve publication access of both well-established urologic scientists and less well-established writers, by allowing interested scientists worldwide to participate fully.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
